US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

705.57

+19.842.89%

Number of Gainers:79

Number of Losers:65

Number of Flat:10

PE:- -

High:707.13

Open:685.68

Low:683.13

Close:685.75

Volume:137.16M

Turnover:4.72B

Market Cap:491.97B

Float Cap:373.47B

Loading ...

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says

MT Newswires Live

Digital Brands Group Delays Filing Quarterly Report for Period Ended June 30, 2026

Strata Credit Union Selects Alkami Digital Banking Platform in Technology Partnership

Skye Bioscience to Merge with Redx, Form Fibrx Therapeutics

Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes

NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am

Coinbase Global Inc: Users May Experience Issues Completing Transactions Through Coinbase Onramp Using Apple Pay

THOMSON REUTERS

Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Outlook Therapeutics Announces $55 Million Equity Offering

Sector Update: Healthcare Stocks Flat to Lower Pre-Bell Friday

MT Newswires Live

Karooooo CEO and Executive Chairman Calisto Isaias Jose Sells USD 658,379.79 in Common Shares

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Clene Q2 Net Loss Widens on Higher Other Expenses

SentinelOne : Oppenheimer Raises Target Price to $27 from $21

THOMSON REUTERS

Onkure Therapeutics Inc. : Oppenheimer Cuts Target Price to $14 from $30

THOMSON REUTERS

Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial

Press Release: Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Invivyd (IVVD) Gets a Buy from Cantor Fitzgerald

Oppenheimer Remains a Buy on SentinelOne (S)

Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK4539/news?page=32"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":705.5808,"timestamp":1787676017134,"preClose":685.7458,"halted":0,"volume":137148935,"delay":0,"changeRate":0.028925,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":19.835022,"latestTime":"08-25 12:40:17 EDT","open":685.6775,"high":707.13104,"low":683.1322,"amount":4720243350.198751,"amplitude":0.034997,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.436531,"peRate":156.391987,"turnoverRate":0.010639,"increases":80,"decrements":64,"flats":7,"marketCap":491972791763.125,"floatMarketCap":373469588299.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":707.13104,"amplitude":0.034997,"preClose":685.7458,"low":683.1322,"pbRate":"5.436531","latestPrice":705.5746,"volume":137162072,"delay":0,"open":685.6775,"prevYearClose":881.5255,"prevWeekClose":700.9769,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":655.4622,"twentyDayClose":704.4272,"sixtyDayClose":779.4826,"secType":"PLATE","market":"US","turnoverRate":0.010641,"peRate":156.391987,"marketCap":491987189663.125,"floatMarketCap":373484140827.25,"timestamp":1787676018876,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":79,"down":65,"flat":10},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:32,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659914054","title":"ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659914054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659914054?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:46","pubTimestamp":1786718801,"startTime":"0","endTime":"0","summary":"ADC Therapeutics (ADCT) faces a tougher regulatory path for LOTIS-5, but strong LOTIS-7 data could create meaningful upside, RBC Capital Markets said in a note emailed Friday.The analysts said they se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","BK4080","ADC","NETL","LENZ","ADCT","BK4231","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147152","title":"Digital Brands Group Delays Filing Quarterly Report for Period Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147152","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659147152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:25","pubTimestamp":1786717558,"startTime":"0","endTime":"0","summary":"Digital Brands Group delays filing quarterly report for period ended June 30, 2026Digital Brands Group flagged a late filing for its Form 10-Q for the quarter ended June 30, 2026.Quarterly report dela","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL5mkgLk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4094","BK4122","DBGI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142250","title":"Strata Credit Union Selects Alkami Digital Banking Platform in Technology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142250","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142250?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:00","pubTimestamp":1786716035,"startTime":"0","endTime":"0","summary":"Strata Credit Union selects Alkami digital banking platform in technology partnershipAlkami Technology entered a strategic technology partnership with Strata Credit Union to deploy Alkami’s Digital Ba","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL9f9p4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKT","BK4023","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659714142","title":"Skye Bioscience to Merge with Redx, Form Fibrx Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2659714142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659714142?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:57","pubTimestamp":1786715855,"startTime":"0","endTime":"0","summary":"Skye Bioscience ( ($SKYE) ) has issued an announcement. On August 14, 2026, Skye Bioscience agreed to acquire U.K.-based Redx Pharma, combining to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/skye-bioscience-to-merge-with-redx-form-fibrx-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/skye-bioscience-to-merge-with-redx-form-fibrx-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142738","title":"Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142738","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142738?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:47","pubTimestamp":1786715255,"startTime":"0","endTime":"0","summary":"Shares in biotech Valneva ($VALN) soared over 20% in early trading today after it and partner Pfizer ($PFE) as it moved closer to bringing its Lyme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/valneva-stock-vln-soars-over-20-on-lyme-disease-vaccine-hopes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/valneva-stock-vln-soars-over-20-on-lyme-disease-vaccine-hopes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","VALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142562","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142562","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142562?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:42","pubTimestamp":1786714975,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:42 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nAQN2MESWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","MF","BK4526","BK4539","BK4113","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659423571","title":"Coinbase Global Inc: Users May Experience Issues Completing Transactions Through Coinbase Onramp Using Apple Pay","url":"https://stock-news.laohu8.com/highlight/detail?id=2659423571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659423571?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:38","pubTimestamp":1786714719,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","LU1861559042.SGD","DAPP","BK4554","BITQ","IBLC","BK4596","CONX","LU1861217088.USD","CRPT","BLCK","COYY","BK4585","BKCH","COIA","BK4535","ICOI","COIN","BK4539","COIW","BK4595","COIO","CONY","BK4551","FIAT","BK4516","BK4588","COIG","BK4112","CONI","FINX","LU1861220207.SGD","COII","CONL","BK4600","FDIG","LU2360107671.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144016","title":"Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144016","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144016?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:31","pubTimestamp":1786714317,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryAcurx Pharmaceuticals IncACXP.OQreported a quarterly adjusted loss of 53 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","ACXP","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144280","title":"Outlook Therapeutics Announces $55 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144280","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144280?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:20","pubTimestamp":1786713643,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-announces-55-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-announces-55-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","LENZ","BK4585","BK4539","BK4007","BK4139","VMRK","BK4588","BK4215","REZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135144","title":"Sector Update: Healthcare Stocks Flat to Lower Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135144","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135144?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:16","pubTimestamp":1786713413,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF  unchanged and the State Street Health Care Select Sector SPDR ETF  declining by 0.2%.Heartflow  stock was up nearly 24% after the company posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.Valneva  shares were up nearly 26% after the company and Pfizer  said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer stock was 0.1% lower premarket.Capricor Therapeutics  shares were up more than 85% after the company said the US Food and Drug Administration is willing to review an amendment to its biologics license application for deramiocel, potentially shifting the drug's focus to upper-limb skeletal muscle function in Duchenne muscular dystrophy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4167","BK4599","CAPR","SG9999002232.USD","LU0289739699.SGD","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","LU0225284248.USD","SG9999011175.SGD","LU1894683348.USD","BK4539","BK4581","BK4592","LU0170899867.USD","BK4585","LU2596442595.SGD","HTFL","LU1883839398.USD","BK4139","LU1894683264.USD","IE00BLSP4452.SGD","SG9999003800.SGD","LU0321505868.SGD","BK4588","LU0058720904.USD","LU0868494617.USD","IE00BLSP4239.USD","LU1066051498.USD","BK4568","IE00B19Z3581.USD","SG9999013999.USD","LU0234572021.USD","BK4550","BK4533","SG9999001176.SGD","LU0306807586.USD","IE00B3T34201.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1023059063.AUD","LU0306806265.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","VALN","OZEM","LU0321505439.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1057294990.SGD","LU0122379950.USD","LU1066053197.SGD","BK4007","PFE","IE0002270589.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144504","title":"Karooooo CEO and Executive Chairman Calisto Isaias Jose Sells USD 658,379.79 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144504","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144504?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:09","pubTimestamp":1786712951,"startTime":"0","endTime":"0","summary":"Karooooo CEO and Executive Chairman Calisto Isaias Jose sells USD 658,379.79 in common sharesKarooooo CEO and Executive Chairman Calisto Isaias Jose sold 10,393 common shares on Aug. 12-13.Shares were","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2BLRWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Karooooo CEO and Executive Chairman Calisto Isaias Jose Sells USD 658,379.79 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","KARO","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416751","title":"VistaGen Q1 Revenue Rises on Licensing Agreement Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416751","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416751?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:44","pubTimestamp":1786711464,"startTime":"0","endTime":"0","summary":"VistaGen Q1 revenue rises onlicensing agreement expirationOverviewUS biopharma firm's fiscal Q1 revenue rose, driven by licensing agreement expirationNet loss for fiscal Q1 narrowed from prior year as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RANI","DARE","BK4007","VTGN","BK4584","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314152","title":"Clene Q2 Net Loss Widens on Higher Other Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711241,"startTime":"0","endTime":"0","summary":"Clene Q2 net loss widens on higher other expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr, driven by higher other expensesCompany closed $7 mln stock offering and extended debt ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139","UNCY","AEON","BK4539","CLNN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659714185","title":"SentinelOne : Oppenheimer Raises Target Price to $27 from $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2659714185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659714185?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:34","pubTimestamp":1786710855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nAZN4TEAXE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","BK4560","LU2286300806.USD","BK4561","BK4585","BK4539","BK4588","S"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141865","title":"Onkure Therapeutics Inc. : Oppenheimer Cuts Target Price to $14 from $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141865?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:34","pubTimestamp":1786710854,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nAZN4TEAXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141812","title":"Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141812","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141812?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:33","pubTimestamp":1786710787,"startTime":"0","endTime":"0","summary":"Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trialA Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio.No","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3SxKqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614134","title":"Press Release: Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614134?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:30","pubTimestamp":1786710600,"startTime":"0","endTime":"0","summary":"-- Clene expects to submit a New Drug Application for CNM-Au8 in ALS. under the accelerated approval pathway in early fourth quarter of 2026. -- Clene announces survival and functional benefit in CNM-Au8-treated","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LABU","LU2125910179.SGD","BK4232","BK4104","LU1923621640.USD","LU2229751404.USD","LU2125910336.SGD","CLNN","BK4585","R","LU2089279066.USD","BK4539","CNM","BK4588","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149472","title":"Invivyd (IVVD) Gets a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149472?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:18","pubTimestamp":1786709921,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald reiterated a Buy rating on Invivyd, with a price target of $10.00. The compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/invivyd-ivvd-gets-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/invivyd-ivvd-gets-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVVD","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659014947","title":"Oppenheimer Remains a Buy on SentinelOne (S)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659014947","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659014947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:18","pubTimestamp":1786709891,"startTime":"0","endTime":"0","summary":"In a report released today, Ittai Kidron from Oppenheimer maintained a Buy rating on SentinelOne, with a price target of $27.00. Kidron covers the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-sentinelone-s-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-sentinelone-s-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4539","OPY","BK4097","BK4585","LU2286300806.USD","BK4127","S","BK4561","BK4560"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146722","title":"Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146722","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146722?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708860,"startTime":"0","endTime":"0","summary":"placement financing. On May 18, 2026, Quince completed a stock-for-stock. merger to acquire Orphai, a clinical-stage biotechnology company,bringing Orphai's lead program, LAM-001, an inhaled formulation of. rapamycin , into the pipeline. LAM-001 is being. developed for the treatment of serious, underserved pulmonary diseases,.Concurrent with the acquisition, Quince entered into a definitive. agreement for a private placement financing with gross upfront proceeds. of $115 million, yielding net proceeds of $103.6 million after deducting. placement agent and other offering expenses of $11.4 million, for the. purchase of shares of Series C non-voting convertible preferred stock and. up to an additional $83 million upon the exercise of warrants (including","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","LENZ","BK4139","BK4539","QNCX","SAPH","BK4007","BK4161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":32,"totalSize":1075,"code":"91000000","status":"200"}]}}